自2023 7月起至2024 9月止，花蓮慈濟醫院泌尿部針對間質性膀胱炎共發表了12篇SCI學術論文：

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions. Int J Mol Sci. 2023 Jul 27;24(15):12055. doi: 10.3390/ijms241512055.
Intravesical injections of autologous platelet-rich plasma for the treatment of refractory interstitial cystitis. Low Urin Tract Symptoms. 2023 Nov;15(6):210-215. doi: 10.1111/luts.12504. Epub 2023 Sep 13.
Multimodal therapies and strategies for the treatment of interstitial cystitis/bladder pain syndrome in Taiwan. Low Urin Tract Symptoms. 2024 Jan;16(1):e12508. doi: 10.1111/luts.12508. Epub 2023 Nov 21.
The Tumor Necrosis Factor-alpha Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection. Int J Mol Sci. 2023 Dec 21;25(1):163. doi: 10.3390/ijms25010163.
Intravesical Botulinum Toxin Injection Plus Hydrodistention Is More Effective in Patients with Bladder Pain-Predominant Interstitial Cystitis/Bladder Pain Syndrome. Toxins (Basel). 2024 Feb 1;16(2):74. doi: 10.3390/toxins16020074.
Cystoscopic characteristic findings of interstitial cystitis and clinical implications. Tzu Chi Med J. 2023 Aug 22;36(1):30-37. doi: 10.4103/tcmj.tcmj_172_23. eCollection 2024 Jan-Mar.
Combination of urinary biomarkers and machine-learning models provided a higher predictive accuracy to predict long-term treatment outcomes of patients with interstitial cystitis/bladder pain syndrome. World J Urol. 2024 Mar 20;42(1):173. doi: 10.1007/s00345-024-04843-3.
Urinary Viral Spectrum in Patients with Interstitial Cystitis/Bladder Pain Syndrome and the Clinical Efficacy of Valacyclovir Treatment. Biomedicines. 2024 Feb 26;12(3):522. doi: 10.3390/biomedicines12030522.
Urine biomarker could be a useful tool for differential diagnosis of a lower urinary tract dysfunction. Tzu Chi Med J. 2023 Dec 13;36(2):110-119. doi: 10.4103/tcmj.tcmj_221_23. eCollection 2024 Apr-Jun.
Using Urine Biomarkers to Differentiate Bladder Dysfunctions in Women with Sensory Bladder Disorders. Int J Mol Sci. 2024 Aug 29;25(17):9359. doi: 10.3390/ijms25179359.
Purine nucleoside phosphorylase as a target for the treatment of interstitial cystitis/bladder pain syndrome with and without Hunner lesions. Sci Rep. 2024 Sep 19;14(1):21898. doi: 10.1038/s41598-024-73280-4.
The Pathomechanism and Current Treatments for Chronic Interstitial Cystitis and Bladder Pain Syndrome. Biomedicines. 2024 Sep 10;12(9):2051. doi: 10.3390/biomedicines12092051.

並且參與了亞洲間質性膀胱炎新版guideline的制訂：

Definition Change and Update of Clinical Guidelines for Interstitial Cystitis and Bladder Pain Syndrome. Homma Y, Akiyama Y, Kim JH, Chuang YC, Jeong SJ, Meng E, Kitta T, Jhang JF, Furuta A, Lee KS, Maeda D.Low Urin Tract Symptoms. 2024 Sep;16(5):e12532. doi: 10.1111/luts.12532.
（作者中Jhang JF為花蓮慈濟泌尿部張嘉峰醫師）